This is a multicenter retrospective, non-interventional observational study to evaluate the efficacy of nMoAbs in HM patients.

This is a multicenter retrospective, non-interventional observational study. The participating centres will retrospectively review all episodes of SARS-CoV-2 infection occurring in HMs identified at their institutions from February 2020 to May 2021 and treated with nMoAbs, to evaluate their efficacy.

Inclusion Criteria:

• All patients must meet all the following criteria for study entry:

  1. Age equal to or greater than 18 years of age.

  2. Diagnosis of HM (acute leukemias, myelodysplastic syndromes, myeloproliferative neoplasms, lymphomas, myeloma, chronic myeloprolipherative disorders) at any stage/status.

  3. Third generation rapid molecular or antigen test positive for SARS-CoV-2 from February 2020 until May 2021

  4. Treatment with anti SARS CoV 2 nMoAbs approved by AIFA

  5. Not hospitalized for COVID-19 at the time of nMoAbs administration

  6. Not on oxygen therapy at the time of nMoAbs administration

  7. At least one of the following symptoms for no more than 10 days:

     • Fever
     • Cough
     • Anosmia
     • Ageusia / dysgeusia
     • Pharyngodynia
     • Asthenia
     • Headache
     • Nausea
     • Diarrhea
     • Myalgia
     • Dyspnea
     • Tachypnea

  8. Signed written informed consent according to ICH/EU/GCP and national local laws (if applicable).

Exclusion Criteria:

• 1. Hematological diseases, other than HM.

  2. Not tested positive for SARS-CoV-2

  3. Patients in disease remission "off therapy" for more than 6 months

  4. Immune plasma treatment in the previous two months

The study population will include patients older than 18 years of age with HM who received nMoAbs, approved by AIFA, for the treatment of SARS-CoV-2 infection.